About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Monthly Archives: June 2010
In the wake of the most recent financial crisis – a question has emerged – inspired by our nation's banks, but now spilling over into the vernacular – too big to fail? It seems reasonable, therefore, to ponder the other … Continue reading
My recent hiatus here on Eye on FDA was not planned or even intentional, it was only a reflection of a very busy schedule lately. What can I say, except that I'm back Jack! It has been some time since … Continue reading
I promise this isn't Pfizer week here at Eye on FDA, though it might seem that way. Yes, my posting yesterday was about their clinical trials information on a special clinical trials YouTube channel. And today, Pfizer announced that the … Continue reading